Valuation: Vista Pharmaceuticals Limited

Market Cap 376M 3.93M 3.45M 3.19M 2.94M 5.56M 5.66M 38.04M 14.92M 185M 14.75M 14.43M 638M P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 443M 4.63M 4.06M 3.76M 3.46M 6.54M 6.67M 44.79M 17.57M 217M 17.37M 16.99M 751M EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
02-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-03 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
25-08-13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-07-15 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
25-05-30 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
25-02-18 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
25-02-12 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
24-11-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
24-08-13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
24-05-28 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
24-02-10 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
24-01-07 Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
23-11-10 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
1 day-0.80%
1 week+5.53%
Current month+3.91%
1 month+3.05%
3 months-1.72%
6 months-9.27%
Current year-8.60%
1 week 7
Extreme 7
7.77
1 month 6.57
Extreme 6.57
8.2
Current year 5.71
Extreme 5.71
8.87
1 year 5.71
Extreme 5.71
11.69
3 years 5.71
Extreme 5.71
19.7
5 years 5.71
Extreme 5.71
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Compliance Officer - 2024-02-09
Director TitleAgeSince
Chairman 76 2014-01-01
Director/Board Member 87 1993-06-15
Director/Board Member 76 2010-02-01
Change 5-day change 1-year change 3-year change Capi.($)
-0.80%+5.53%-34.10%-24.62% 4.82M
+1.10%+2.06%+15.45%+81.05% 48.17B
+0.36%-4.47%+66.16%+115.81% 35.47B
+0.80%-0.94%-3.09%+39.50% 12.04B
+0.20%-1.68%+17.05%+90.41% 11.79B
+0.75%+1.53%+33.50%+127.47% 9.15B
+1.01%-2.12%+18.42%+37.37% 6.91B
+1.33%-1.06%+48.46%-4.10% 6.95B
+0.17%+1.77%+3.87%+228.32% 6.79B
-5.52%-11.93%-22.06%+7.41% 5.77B
Average -0.06%-1.76%+14.37%+69.86% 14.3B
Weighted average by Cap. +0.49%-2.30%+27.44%+87.68%

Financials

2024 2025
Net sales 103M 1.07M 943K 873K 803K 1.52M 1.55M 10.41M 4.08M 50.52M 4.04M 3.95M 174M 101M 1.05M 923K 855K 787K 1.49M 1.52M 10.19M 4M 49.47M 3.95M 3.87M 171M
Net income -45.12M -471K -413K -383K -352K -666K -679K -4.56M -1.79M -22.16M -1.77M -1.73M -76.52M -46.49M -486K -426K -395K -363K -687K -700K -4.7M -1.84M -22.83M -1.82M -1.78M -78.84M
Net Debt 78.7M 822K 721K 668K 615K 1.16M 1.19M 7.96M 3.12M 38.65M 3.09M 3.02M 133M 66.71M 697K 611K 566K 521K 985K 1M 6.75M 2.65M 32.76M 2.62M 2.56M 113M
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
26-07-14 7.440 -0.80% 2,243
26-07-13 ₹7.500 +3.02% 6,989
26-07-10 ₹7.280 +0.69% 904
26-07-09 ₹7.230 -2.03% 5,826
26-07-08 ₹7.380 +4.68% 11,401
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock